Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$2.11
+1.0%
$1.90
$0.77
$4.08
$291.78M1.4922,846 shs662,949 shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$9.29
+10.5%
$8.10
$2.20
$12.78
$254.45M-0.66190,493 shs138,331 shs
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$1.89
+2.2%
$2.08
$1.04
$3.93
$288.35M1.332.28 million shs1.12 million shs
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$0.94
+2.6%
$0.79
$0.52
$5.17
$79.76M1.771.10 million shs1.04 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
0.00%-0.95%+7.73%-29.63%+42.18%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
0.00%-22.13%-1.41%+99.05%+37.96%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
0.00%-3.65%-19.57%+10.12%-46.22%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
0.00%+4.75%+1.93%-44.24%-77.78%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.83 of 5 stars
4.63.00.00.02.75.00.0
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.585 of 5 stars
3.54.00.00.01.91.70.6
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.6186 of 5 stars
3.50.00.04.23.01.70.6
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
4.4039 of 5 stars
4.13.00.04.72.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
3.11
Buy$13.13522.04% Upside
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
3.00
Buy$18.5099.14% Upside
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
3.00
Buy$5.50191.01% Upside
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
2.13
Hold$6.11547.49% Upside

Current Analyst Ratings Breakdown

Latest STRO, DBVT, HRTX, and CMPX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.00
5/19/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$1.00 ➝ $0.80
5/9/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
5/5/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $16.00
5/1/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $15.00
4/29/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00
4/28/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/22/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/21/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
4/21/2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/11/2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$850K343.27N/AN/A$1.17 per share1.80
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$15.73M16.18N/AN/A$7.27 per share1.28
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
$148.52M1.94N/AN/A($0.23) per share-8.22
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$66.43M1.20N/AN/A$2.45 per share0.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$42.49M-$0.41N/AN/AN/AN/A-32.37%-30.67%8/11/2025 (Estimated)
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$72.73M-$4.92N/AN/AN/A-815.73%-106.07%-76.17%7/29/2025 (Estimated)
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$110.56M-$0.06N/AN/AN/A-20.31%N/A-12.72%8/5/2025 (Estimated)
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$106.79M-$2.98N/AN/AN/A-77.01%-101.89%-28.69%8/12/2025 (Estimated)

Latest STRO, DBVT, HRTX, and CMPX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$0.12-$0.12N/A-$0.12N/AN/A
5/8/2025Q1 2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million
5/6/2025Q1 2025
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.01$0.01+$0.02$0.01$37.08 million$38.90 million
4/11/2025Q4 2024
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A-$1.10N/A-$1.10N/A$0.51 million
3/13/2025Q4 2024
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$0.86-$2.96-$2.10-$0.89$10.44 million$14.00 million
2/27/2025Q4 2024
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$0.10-$0.11-$0.01-$0.11N/AN/A
2/27/2025Q4 2024
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
-$0.03$0.02+$0.05$0.02$37.37 million$40.78 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/AN/A
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/AN/AN/AN/AN/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/A
31.84
31.84
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A
2.22
2.22
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
N/A
2.28
1.74
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/A
3.09
3.09

Institutional Ownership

CompanyInstitutional Ownership
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
68.43%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
71.74%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
80.01%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
96.99%

Insider Ownership

CompanyInsider Ownership
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
29.80%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
1.90%
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
5.86%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
20138.28 million98.38 millionNot Optionable
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
8027.39 million20.18 millionOptionable
Heron Therapeutics, Inc. stock logo
HRTX
Heron Therapeutics
300152.56 million143.33 millionOptionable
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
24084.46 million77.59 millionOptionable

Recent News About These Companies

Sutro Biopharma downgraded to Neutral from Buy at H.C. Wainwright
Sutro Biopharma presents expanded data from REFRalphaME-01 trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Compass Therapeutics stock logo

Compass Therapeutics NASDAQ:CMPX

$2.11 +0.02 (+0.96%)
Closing price 04:00 PM Eastern
Extended Trading
$2.15 +0.04 (+1.85%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

DBV Technologies stock logo

DBV Technologies NASDAQ:DBVT

$9.29 +0.88 (+10.48%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Heron Therapeutics stock logo

Heron Therapeutics NASDAQ:HRTX

$1.89 +0.04 (+2.16%)
Closing price 04:00 PM Eastern
Extended Trading
$1.88 0.00 (-0.26%)
As of 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Sutro Biopharma stock logo

Sutro Biopharma NASDAQ:STRO

$0.94 +0.02 (+2.64%)
Closing price 04:00 PM Eastern
Extended Trading
$0.94 0.00 (-0.03%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.